| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 17.3 | 13.9 | 0.0 |
| Total income | 17.3 | 13.9 | 0.0 |
| Profit before exceptional items & tax | 3.5 | 1.9 | 0.0 |
| Profit before tax | 3.5 | 1.9 | 0.0 |
| Net profit | 2.8 | 1.4 | 0.0 |
| Operating margin | 20.2% | 13.7% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +100.00% |
|---|
BSE results filing, BSE: 544759. Figures extracted from the filing.
Goldline Pharmaceutical Ltd: key numbers
- Share price
- ₹33.00
- Market cap
- ₹31.68 Cr
- Revenue (annual)
- ₹31.20 Cr
- Net profit (annual)
- ₹4.12 Cr
- P/E (TTM)
- 7.7×Sector 47.4×
- Promoter holding
- 57.29%
- FII holding
- 5.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Goldline Pharmaceutical Ltd
All →Goldline Pharmaceutical Annual General Meeting
Goldline Pharmaceutical Ltd held its 22nd Annual General Meeting on August 29, 2026, where directors and key management presented financial performance and future business outlook.
Goldline Pharmaceutical Promoter Buying
Promoter Swapan Khandelwal increased his stake in Goldline Pharmaceutical Limited by 0.81% through an open market acquisition of 78,000 shares.
Goldline Pharmaceutical Other Announcement
Goldline Pharmaceutical Ltd announced the closure of its Register of Members and Share Transfer Books from August 23 to August 29, 2026, for its AGM.
Goldline Pharmaceutical Annual Report
Goldline Pharmaceutical Limited submitted its Annual Report for the financial year 2025-26, including the notice for the upcoming AGM on August 29, 2026.
Goldline Pharmaceutical Annual General Meeting
Goldline Pharmaceutical Limited has issued a notice for its 22nd Annual General Meeting, scheduled for August 29, 2026. The meeting will address financial statements, dividends, and director re-appointments.
Goldline Pharmaceutical Capital Structure Change
Executive Director Mr. Prashant Shrikrishna Karkare acquired 27,000 equity shares of Goldline Pharmaceutical via an open market purchase. This is a non-promoter insider transaction.